Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178816 | 0.87 | JAK2 (0.70) | JAK2ROCK2BTKJAK1TYK2 | |
| SCHEMBL138910 | 0.85 | JAK2 (0.69) | JAK2ROCK2BTKJAK1TYK2 | |
| SCHEMBL178817 | 0.83 | JAK2 (0.82) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL10271646 | 0.83 | JAK2 (0.82) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL138161 | 0.82 | JAK2 (1.00) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL143704 | 0.82 | JAK2 (0.64) | JAK2ROCK2BTKJAK1TYK2 | |
| SCHEMBL178699 | 0.81 | JAK2 (1.00) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL178704 | 0.81 | JAK2 (0.86) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL138052 | 0.80 | JAK2 (1.00) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL15800318 | 0.79 | JAK2 (0.83) | JAK2BTKJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885ROCK2 365/4885BTK 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.